Stifel Financial
CYTK icon

Stifel Financial’s Cytokinetics CYTK Stock Holding History

Stifel Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84M Buy
56,834
+2,390
+4% +$172K ﹤0.01% 1431
2026
Q1 		$3.59M Buy
54,444
+6,473
+13% +$411K ﹤0.01% 1556
2025
Q4 		$3.05M Buy
47,971
+3,345
+7% +$208K ﹤0.01% 1630
2025
Q3 		$2.45M Buy
44,626
+26,880
+151% +$1.11M ﹤0.01% 1770
2025
Q2 		$586K Sell
17,746
-968
-5% -$33.7K ﹤0.01% 2682
2025
Q1 		$752K Sell
18,714
-6,329
-25% -$291K ﹤0.01% 2415
2024
Q4 		$1.18M Sell
25,043
-24
-0.1% -$1.25K ﹤0.01% 2150
2024
Q3 		$1.32M Buy
25,067
+1,959
+8% +$109K ﹤0.01% 2037
2024
Q2 		$1.25M Sell
23,108
-7
-0% -$423 ﹤0.01% 2018
2024
Q1 		$1.62M Buy
23,115
+8
+0% +$619 ﹤0.01% 1878
2023
Q4 		$1.93M Sell
23,107
-458
-2% -$16.6K ﹤0.01% 1693
2023
Q3 		$694K Sell
23,565
-2,112
-8% -$70.3K ﹤0.01% 2297
2023
Q2 		$838K Buy
25,677
+46
+0.2% +$1.7K ﹤0.01% 2191
2023
Q1 		$902K Buy
25,631
+522
+2% +$21.3K ﹤0.01% 2127
2022
Q4 		$1.15M Sell
25,109
-2,006
-7% -$86.3K ﹤0.01% 1894
2022
Q3 		$1.31M Sell
27,115
-136
-0.5% -$6.55K ﹤0.01% 1769
2022
Q2 		$1.07M Sell
27,251
-1,066
-4% -$42.9K ﹤0.01% 1943
2022
Q1 		$1.04M Sell
28,317
-152
-0.5% -$5.4K ﹤0.01% 2083
2021
Q4 		$1.3M Sell
28,469
-1,779
-6% -$68.6K ﹤0.01% 1929
2021
Q3 		$1.08M Buy
30,248
+7,116
+31% +$209K ﹤0.01% 2035
2021
Q2 		$458K Buy
23,132
+11
+0% +$258 ﹤0.01% 2635
2021
Q1 		$538K Buy
23,121
+8,661
+60% +$185K ﹤0.01% 2438
2020
Q4 		$301K Buy
14,460
+2,433
+20% +$44.5K ﹤0.01% 2593
2020
Q3 		$260K Sell
12,027
-739
-6% -$17.3K ﹤0.01% 2484
2020
Q2 		$301K Buy
+12,766
New +$239K ﹤0.01% 2363

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stifel Financial's CYTK Position: Q2 2026 in Review

Stifel Financial increased its Cytokinetics (CYTK) stake by 4.4% in Q2 2026, buying an estimated $172K and bringing the position to 56,834 shares worth $4.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1431.

Stifel Financial first reported a position in CYTK in Q2 2020 and has held it in 25 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Stifel Financial held 56,834 shares of Cytokinetics worth $4.84M as of Q2 2026.
  • Stifel Financial bought 2,390 Cytokinetics shares in Q2 2026, an estimated $172K.
  • Cytokinetics made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #1431 holding.
  • Stifel Financial first reported a position in Cytokinetics in Q2 2020 and has held it in 25 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.